Wednesday, April 25, 2012

Reuters: Mergers News: Deutsche Bank says Actavis deal shores up capital

Reuters: Mergers News
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Deutsche Bank says Actavis deal shores up capital
Apr 25th 2012, 21:00

FRANKFURT, April 25 | Wed Apr 25, 2012 5:00pm EDT

FRANKFURT, April 25 (Reuters) - Deutsche Bank said it will raise its core tier one capital position by 290 million euros ($382 million) thanks to drug maker Watson's purchase of Actavis, making the lender a beneficiary of the deal.

Transferring de facto ownership of Actavis from Deutsche Bank, which has billions in debt exposure to the Swiss generic drugmaker, to U.S.-based Watson allows the bank to free up a capital buffer it was forced to set aside to cover for potential Actavis losses.

The sale triggered an impairment charge of 257 million euros in the first quarter but overall the deal will have a net positive impact on Deutsche Bank's core tier 1 capital ratio of about 0.06 percentage points in 2012, the lender said on Wednesday.

"This further demonstrates the Group's commitment to reducing non-core legacy positions and associated risk in a capital efficient manner," it said in a statement.

At the end of 2011, the bank's core tier one capital ratio stood at 9.5 percent.

Germany's flagship lender was left holding billions of euros of Actavis debt after financing a leveraged buyout in 2007 by Icelandic tycoon Bjorgolfur Thor Bjorgolfsson.

Deutsche, which is due to unveil first-quarter earnings on Thursday, already took a 400 million euro impairment charge on Actavis in the fourth quarter.

Watson said earlier on Wednesday it agreed to buy Actavis for at least 4.25 billion euros, in a deal that cements its status as one of the world's biggest suppliers of generic drugs.

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 comments:

Post a Comment

 
Great HTML Templates from easytemplates.com.